

PRESS ANNOUNCEMENT, 10 MAY 2010

INTERNATIONAL BREAKTHROUGH FOR SWEDISH BIOTECH COMPANY

Acute blood poisoning, also known as sepsis, is a life-threatening condition causing high mortality. Every year, several million people are affected and mortality is 30 percent. The illness progresses quickly and is difficult to treat, and is the leading cause of death in intensive care wards. There is now a new unique treatment which has been developed by Alteco Medical AB in Lund. The company was started in 2002 and after intensive research and development work the Alteco® LPS Adsorber was CE marked in 2005. It is a simple solution which saves lives. It acts extracorporeally, i.e. it purifies the blood outside the body. Its efficacy is confirmed by data from clinical studies on various patient categories. Alteco Medical AB holds the patent and trademark, which is valid in many countries of the world.

Patients who are affected by acute blood poisoning develop a general inflammatory reaction which can be extremely serious and often results in organ failure. The reaction is caused by lipopolysaccharide (LPS), a fatty acid which is classed as a toxin due to its ability to provoke severe immune reactions. Alteco® LPS Adsorber absorbs and removes LPS from the blood before it is returned.

"The product has been commercially available for two and a half years. Sales have progressed extremely well. Alteco Medical AB sells its product through distributors in some fifteen countries. Recently, Alteco Medical AB received a major order from Russia with a market value of three million, which will be delivered in the near future", says Christer Nerme.

"It is a difficult challenge for a biotech company to be first on the market with a new type of treatment. An order of this magnitude is an acknowledgement of all the work we have invested. This was an important milestone, which we have now passed when we carry on with the work of building Alteco Medical AB for the future," says Jonas Jönmark, CEO of Alteco Medical AB.

"We have developed a unique product which saves lives in a difficult to treat area of disease. Our treatment method will set a new standard for the way in which severe and acute blood poisoning is treated throughout the world," says Anders Althin, chairman of the board of directors of Alteco Medical AB.

ABOUT CHRISTER NERME

Christer Nerme, previous CEO of Alteco Medical AB, will stay on as Senior Vice President in charge of several countries and will back up the new CEO.

ABOUT JONAS JÖNMARK

Jonas Jönmark took over as CEO of Alteco Medical AB in April 2010. He has previously occupied various sales and marketing posts in the pharmaceutical industry, the most recent as Vice President Sales for AstraZeneca Sweden, and prior to this as Nordic Sales Director at Astellas Pharma A/S.

ABOUT ANDERS ALTHIN

From 1975 to 1984, Anders Althin was CEO and group chief executive of the medical technology company Gambro AB. During his time there Gambro AB emerged as a global group. In 1985, Anders Althin started a new medical technology company, Althin Medical AB. In just 15 years, Althin Medical became a major global company operating in every corner of the world. In 2000, Anders Althin sold the company to start the ESALP Invest AB investment company in 2001. Alteco Medical AB is part of the ESALP group, which is owned by Anders Althin and family.

CONTACT

Jonas Jönmark

Mobile: +46 (0)70 365 54 00

Email: Jonas.Jonmark@altecomedical.com